Proteogenix Inc., a Portland, Ore.-based developer of proteomic and genomic tests to detect and monitor fetal disorders , has raised $20 million in Series B funding, according to a regulatory filing. Backers include Burrill & Co., New Leaf Ventures and TPG Ventures. www.proteogenix.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.